The India diagnostic labs market is expected to grow at a CAGR of 5.20% during the forecast period of 2025-2034 driven by the adoption of advanced technologies, including molecular diagnostics and automation across the region. Enhancing the accuracy and efficiency of diagnostic services is positioning Indian labs at the forefront of innovation. Supportive government policies and initiatives aimed at improving healthcare infrastructure have facilitated the growth and modernization of diagnostic laboratories in India.

The latest trends and outlook for the India Diagnostic Laboratories Market, including size, market share, and industry insights. Diagnostic Laboratories Market outlook 2025.

As of 2023, well over ** thousand pathology labs were run by standalone centers, accounting for the majority shares of pathology labs. Comparatively, about ** thousand labs were run by small and medium private hospitals, with a market share of *** percent.

The India Diagnostic Labs market is projected to grow with more than 11.50% CAGR from 2024 to 2029, rising demand for point-of-care testing.

Discover insights into the India Diagnostic Laboratories Industry, including market size, share, revenue, major players, and Top Service Provider, Top Captive Players.

In financial year 2021, the diagnostic sector in India was valued at *** billion Indian rupees. With the increasing spending on healthcare, it was projected to expand at a compound annual growth rate of ** percent, reaching **** trillion Indian rupees by 2026.

The size of the India In-Vitro Diagnostics Market market was valued at USD 1.71 Million in 2023 and is projected to reach USD 2.67 Million by 2032, with an expected CAGR of 6.58% during the forecast period. The India in-vitro diagnostics (IVD) market is confined to medical devices that are employed to perform tests on samples derived from or on parts of the human body, for the most part for diagnostic purposes. Some of these tests include a blood test, urine test and test on tissues in a bid to diagnose diseases, keep track of the goings-on in a patient’s health and to average the impact of treatment. Most of the relevant uses pertain to the actual identification of diseases for example diabetes or cancer screening and measurement of ongoing conditions, and early screening for illnesses. Key factors that are pushing this market are improving healthcare consciousness among people, technological progress, and a new focus on early diagnostics and individual treatment. Some current trends observed are, point of care testing, the use of artificial intelligence to enhance test accuracy and, an increasing variety of tests for chronic and diseases caused by infections. Recent developments include: In June 2022, Genes2Me Pvt. Ltd launched the CoviEasy Self-test Rapid Antigen kit for COVID-19, which is supported by an AI-driven mobile app., In February 2022, Mylab Discovery Solutions launched CoviSwift, a point-of-care (POC) testing solution comprising the CoviSwift assay and Compact-Q machines and process 16 samples within 40 minutes, four times faster than the typical RT-PCR testing procedure.. Key drivers for this market are: High Prevalence of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics; Rising Awareness and Acceptance of Personalized Medicine and Companion Diagnostics. Potential restraints include: Stringent Regulations, Cumbersome Reimbursement Procedures. Notable trends are: Molecular Diagnostics Segment is Expected to Grow in the India In-Vitro Diagnostics Market Over the Forecast Period.

In financial year 2023, the clinical chemistry/pathology segment had the highest market size, valued at *** billion U.S. dollars in India. The most common tests done for clinical pathology are complete blood count (CBC), liver function test, and lipid profile. The total pathology market size was *** billion U.S. dollars for the same year.

The poultry diagnostic testing market is estimated to rise from US$ 956.3 Million in 2022 and projected to reach US$ 1.2 Billion by 2032 with a CAGR of 2.4% from 2022 to 2032.

Report Attribute	Details
Poultry Diagnostic Testing Market Value (2022)	US$ 956.3 Million
Poultry Diagnostic Testing Market Forecast Value (2032)	US$ 1.2 Billion
Poultry Diagnostic Testing Market CAGR (2022 to 2032)	2.4%

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 2.4% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2016 to 2021
Forecast Period	2022 to 2032
Quantitative Units	Revenue in US$ Million and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Test Type Disease Type Region
Regions Covered	North America Latin America Europe East Asia South Asia Oceania Middle East and Africa
Key Countries Profiled	USA Canada Brazil Argentina Germany UK France Spain Italy Nordics BENELUX Australia & New Zealand China India ASEAN GCC South Africa
Key Companies Profiled	IDEXX Laboratories, Inc. QIAGEN N.V. Thermo Fisher Scientific Inc. Zoetis, Inc. GD Animal Health IDvet AffiniTech, LTD. AgroBioTek Internacional BioNote, Inc. BioChek Boehringer Ingelheim MEGACOR Diagnostik GmbH BioinGentech Biotechnologies, Inc.
Customization	Available Upon Request

According to Future Market Insights research, during the projected period, the Global point-of-care diagnostics market is expected to grow at a CAGR of 6.8%. The market value is projected to increase from US$ 38.7 Billion in 2023 to US$ 74.8 Billion by 2033. The point-of-care diagnostics market was valued at US$ 36.6 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 5.8% in 2023.

Data Points	Market Insights
Market Value 2022	US$ 36.6 Billion
Market Value 2023	US$ 38.7 Billion
Market Value 2033	US$ 74.8 Billion
CAGR 2023 to 2033	6.8%
Share of Top 5 Countries	56.5%
Key Players	The key players in the Global Point-of-Care Diagnostics Market Are F. Hoffmann-La Roche Ltd, Becton Dickinson & Company, Cepheid (Danaher),Siemens Healthineers, Abbott, Diasorin S.p.a., Thermo Fisher Scientific Inc. , Qiagen, BIOMÉRIEUX, Hologic Inc., Bio Rad Laboratories, Quidel Corporation, EKF Diagnostics, SEKISUI Diagnostics, DiaSys-Diagnostic Systems GmbH, InBios International, Inc., Jiangsu Mole Bioscience Co., Ltd., ACON Laboratories, Inc., Visby Medical, Inc., UNIMA, INC.

Scope of the Global Point-of-Care Diagnostics Industry Report

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2012 to 2022
Market Analysis	USD Million for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, and GCC Countries
Key Segments Covered	Test Type, Sample, Product, End User, Region
Key Companies Profiled	F. Hoffmann-La Roche Ltd Becton Dickinson & Company Cepheid (Danaher) Siemens Healthineers Abbott Diasorin S.p.a. Thermo Fisher Scientific Inc. Qiagen BIOMÉRIEUX Hologic Inc. Bio Rad Laboratories Quidel Corporation EKF Diagnostics SEKISUI Diagnostics DiaSys-Diagnostic Systems GmbH InBios International, Inc. Jiangsu Mole Bioscience Co., Ltd. ACON Laboratories, Inc. Visby Medical, Inc. UNIMA, INC.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing	Available upon Request

The global sales of clinical diagnostics is estimated to be worth USD 86.5 billion in 2025 and anticipated to reach a value of USD 147.2 billion by 2035. Sales are projected to rise at a CAGR of 5.5% over the forecast period between 2025 and 2035. The revenue generated by clinical diagnostics in 2024 was USD 82.6 billion.

Attributes	Key Insights
Historical Size, 2024	USD 82.6 billion
Estimated Size, 2025	USD 86.5 billion
Projected Size, 2035	USD 147.2 billion
CAGR (2025 to 2035)	5.5%

Semi-annual Market Update for the Clinical Diagnostics Industry

Particular	Value CAGR
H1	6.4% (2024 to 2034)
H2	6.1% (2024 to 2034)
H1	5.5% (2025 to 2035)
H2	5.1% (2025 to 2035)

Analysis of Top Countries Using Clinical Diagnostic Tools

Countries	Value CAGR (2025 to 2035)
United States	3.4%
Germany	3.9%
UK	3.7%
France	4.2%
China	5.6%
South Korea	5.1%
India	6.0%

Clinical Diagnostics Industry Analysis by Top Investment Segments

By Product type	Reagents and Kits
Value Share (2025)	63.3%

By Test	Infectious Disease
Value Share (2025)	38.6%

The India In-Vitro Diagnostics (IVD) market is experiencing robust growth, projected to reach a market size of $1.71 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 6.58% from 2025 to 2033. This expansion is fueled by several key factors. Rising prevalence of chronic diseases like diabetes, cancer, and cardiovascular ailments, coupled with an aging population, significantly increases the demand for diagnostic testing. Government initiatives promoting healthcare infrastructure development and affordable healthcare access further contribute to market growth. Technological advancements in areas like molecular diagnostics and automation are driving efficiency and accuracy in testing, while the increasing adoption of point-of-care testing (POCT) enhances accessibility, particularly in remote areas. The market is segmented by test type (clinical chemistry, molecular diagnostics, etc.), product (instruments, reagents), usability (disposable/reusable), application (infectious diseases, oncology), and end-user (diagnostic labs, hospitals). Major players like Abbott Laboratories, Roche, and Siemens are actively shaping the market landscape through strategic partnerships, product launches, and investments in research and development. The competitive landscape is characterized by both multinational corporations and domestic players. While multinational companies enjoy a significant market share due to their advanced technologies and established distribution networks, domestic companies are witnessing growth, particularly in providing affordable solutions tailored to the specific needs of the Indian market. Challenges remain, including infrastructure limitations in some regions, variations in healthcare spending across different segments of the population, and regulatory hurdles. Nevertheless, the overall growth trajectory of the India IVD market remains positive, driven by improving healthcare infrastructure, increasing awareness of preventive healthcare, and advancements in diagnostic technologies. Future growth is likely to be influenced by factors such as the expansion of medical insurance coverage, the growing adoption of telehealth, and the government's focus on improving healthcare outcomes. Recent developments include: In June 2022, Genes2Me Pvt. Ltd launched the CoviEasy Self-test Rapid Antigen kit for COVID-19, which is supported by an AI-driven mobile app., In February 2022, Mylab Discovery Solutions launched CoviSwift, a point-of-care (POC) testing solution comprising the CoviSwift assay and Compact-Q machines and process 16 samples within 40 minutes, four times faster than the typical RT-PCR testing procedure.. Key drivers for this market are: High Prevalence of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics; Rising Awareness and Acceptance of Personalized Medicine and Companion Diagnostics. Potential restraints include: High Prevalence of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics; Rising Awareness and Acceptance of Personalized Medicine and Companion Diagnostics. Notable trends are: Molecular Diagnostics Segment is Expected to Grow in the India In-Vitro Diagnostics Market Over the Forecast Period.

The In Vitro Diagnostics (IVD) test kit market is experiencing robust growth, driven by factors such as the rising prevalence of chronic diseases, an aging global population, and technological advancements leading to more sophisticated and accurate diagnostic tools. The market, estimated at $80 billion in 2025, is projected to maintain a 5% Compound Annual Growth Rate (CAGR) through 2033, reaching approximately $110 billion. This growth is fueled by increasing demand across various segments, including laboratories, hospitals, and point-of-care testing settings. The shift towards personalized medicine and proactive healthcare is further accelerating adoption. Key players like Abbott Laboratories, Roche, and Siemens are investing heavily in R&D to develop innovative diagnostic solutions, such as rapid diagnostic tests and molecular diagnostics, contributing to market expansion. However, factors such as stringent regulatory approvals and high costs associated with new technologies may pose some restraints to market growth. The market segmentation reveals a significant share for reagents and kits, reflecting the consumable nature of these products, and a growing segment for data management software, highlighting the increasing importance of data analytics in diagnostics. Regional analysis shows strong growth in North America and Europe, driven by well-established healthcare infrastructure and high healthcare expenditure. Emerging markets in Asia-Pacific, particularly in India and China, are also presenting significant growth opportunities due to expanding healthcare access and rising disposable incomes. The strong growth trajectory of the IVD test kit market is expected to continue, fueled by ongoing technological advancements, including the integration of artificial intelligence and machine learning for improved diagnostic accuracy and efficiency. The increasing focus on early disease detection and preventive care is also driving demand. Furthermore, the rise of home-based diagnostics and patient self-testing is expected to significantly influence market growth in the coming years. While regulatory hurdles and pricing challenges remain, the overall market outlook remains positive, presenting significant opportunities for industry players to capitalize on technological innovations and expanding healthcare needs globally. The increasing adoption of advanced molecular diagnostic techniques, such as PCR and next-generation sequencing, is expected to further contribute to market expansion.

Indian In-vitro Diagnostics (IVD) Market size was valued at USD 2.1 Billion in 2023 and is projected to reach USD 3.5 Billion by 2031, growing at a CAGR 7.56% from 2024-2031.

Indian In-vitro Diagnostics (IVD) Market: Definition/Overview

In-vitro diagnostics are defined as medical devices and consumables that are utilized for performing tests on samples, such as blood, urine, and tissue, which have been obtained from the human body. These tests are designed to be conducted outside the human body in laboratory settings. Through these diagnostics, various conditions are detected, and the effectiveness of treatments is monitored.

Rapid Diagnostic Kits Market for Indian Ocean Region Countries (France, India, Australia, Indonesia, Singapore, Sri Lanka, Madagascar) by Product (Professional, OTC), Platform (Immunoassay, Molecular), Application (Infectious Diseases, Cardiac, Urinalysis, Cholesterol), End User (Hospital, Diagnostic Lab) - Forecast to 2029

Snapshot img

Multiplexed Diagnostics Market Size 2025-2029

The multiplexed diagnostics market size is forecast to increase by USD 14.32 billion, at a CAGR of 14.9% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing incidence of infectious and chronic diseases. This trend is fueled by the rising demand for early and accurate diagnosis, enabling effective treatment and management of various health conditions. Furthermore, the introduction of new multiplexed diagnostic technologies is expanding the market's potential, offering improved efficiency, cost savings, and enhanced diagnostic capabilities. However, the market faces challenges, including regulatory and approval hurdles. These obstacles necessitate extensive clinical validation, stringent regulatory compliance, and lengthy approval processes, which can delay market entry and increase costs for diagnostic companies.
To capitalize on market opportunities and navigate these challenges effectively, strategic partnerships, robust regulatory strategies, and continuous innovation are essential. Companies must focus on developing user-friendly, cost-effective, and accurate diagnostic solutions to meet the evolving needs of healthcare providers and patients.

What will be the Size of the Multiplexed Diagnostics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by the integration of advanced technologies and the growing demand for efficient, accurate, and cost-effective diagnostic solutions. Clinical decision support systems are increasingly relying on multiplexed diagnostics to enhance patient care, with applications spanning various sectors. Clinical sensitivity and specificity are crucial considerations in the development of these technologies. Multiplexed PCR assays, digital microfluidics, and immunoassay platforms are among the solutions addressing these requirements. Assay validation and data analysis software play essential roles in ensuring accuracy and reliability. Lab automation, including liquid handling systems and lab-on-a-chip technology, streamline workflows and reduce human error.

Point-of-care diagnostics and next-generation sequencing are gaining traction, enabling rapid and precise disease screening. Optical detection systems, micro-total analysis systems, and fluorescence microscopy contribute to the detection and analysis of biomarkers. Molecular diagnostics, proteomic profiling, and genetic testing are essential components of the evolving diagnostic landscape. Quality control metrics and image processing algorithms ensure consistent results and maintain the integrity of data. Multiplexed ELISA and microarray technology further expand the capabilities of multiplexed diagnostics. The ongoing unfolding of market activities reflects the continuous integration of these technologies, shaping the future of diagnostic solutions and improving patient outcomes.

How is this Multiplexed Diagnostics Industry segmented?

The multiplexed diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Kits and reagents
  Instruments and accessories


Application

  Infectious disease
  Oncology
  Autoimmune diseases
  Cardiac diseases
  Others


End-user

  Diagnostic labs
  Hospitals
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Product Insights

The kits and reagents segment is estimated to witness significant growth during the forecast period.

In the dynamic realm of diagnostic technologies, the market witnesses significant growth, driven by the increasing demand for accurate and efficient diagnostic solutions. This market encompasses a range of advanced technologies, including mass spectrometry, biomarker detection, digital microfluidics, multiplexed PCR assays, cellular analysis, electrochemical sensors, assay validation, cytometric bead arrays, immunoassay platforms, high-throughput screening, data analysis software, and various other techniques. These technologies enable the simultaneous detection of multiple biomarkers, pathogens, or genetic factors from a single sample, enhancing the clinical specificity and sensitivity of diagnostic tests. For instance, multiplexed PCR assays facilitate the detection of multiple genetic mutations or infectious agents, while microarray technology and proteomic profiling offer insights into complex biological systems.

Moreover, the integration of lab automation, point-of-care diag

The diverse Indian diagnostics devices market is segmented by various factors, offering a granular view of its components. This segmentation facilitates a deeper understanding of market dynamics and growth potential within specific niches.Type:Immunodiagnostics (including ELISA, immunofluorescence)Clinical chemistry (analyzers and reagents)Tissue diagnostics (histopathology, cytology)Haematology (complete blood counts, coagulation testing)Point-of-care tests (rapid diagnostic tests, blood glucose meters)Molecular diagnostics (PCR, Next-Generation Sequencing)Others (e.g., microbiology, urinalysis)Product Type:Instruments/analyzers (ranging from basic to advanced systems)Reagents and kits (consumables essential for diagnostic tests)Application:Infectious disease (bacterial, viral, parasitic infections)Oncology (cancer diagnostics and monitoring)Hormone testing (endocrine disorders)Diabetes (glucose monitoring, HbA1c testing)Cardiac diagnostics (cardiac markers, ECG)Others (e.g., autoimmune diseases, genetic testing)End User:Diagnostic chains (large-scale diagnostic service providers)Individual diagnostic laboratories (independent labs)Hospital laboratories (in-house diagnostic facilities)Others (e.g., research institutions, physician offices) Recent developments include: September 2021: Abbott launched its Alinity m Resp-4-Plex molecular diagnostic test, which can detect and differentiate between SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) in a single test., July 2021: Bio-Rad Laboratories launched its QXDx AutoDG ddPCR System, a fully automated droplet digital PCR (ddPCR) system for high-throughput research and clinical laboratories.. Notable trends are: Growing awareness and focus on preventive healthcare is driving the market growth.

Comprehensive dataset of 49,750 Medical laboratories in India as of July, 2025. Includes verified contact information (email, phone), geocoded addresses, customer ratings, reviews, business categories, and operational details. Perfect for market research, lead generation, competitive analysis, and business intelligence. Download a complimentary sample to evaluate data quality and completeness.

The in-vitro diagnostics kit market is estimated to advance at a CAGR of 4.40%, reaching US$ 18.8 billion through the forecasted period. The estimated market size of the market by 2024 is US$ 12.2 billion. Various market forces influence the market.

Attributes	Key Insights
Estimated Market Size in 2024	US$ 12.2 billion
Projected Market Value in 2034	US$ 18.8 billion
Value-based CAGR from 2024 to 2034	4.40%

Demand Analysis of In-vitro Diagnostics Kit Market from 2019 to 2023 vs. Outlook from 2024 to 2034

Historical CAGR from 2019 to 2023	5.00%
Forecast CAGR from 2024 to 2034	4.40%

Country-wise Analysis

Countries	Forecasted CAGR
The United States	2.7%
France	1.6%
Spain	3.3%
China	5.6%
India	6.7%

Category-wise Insights

Category	Application - Infectious Diseases
Market Share in 2024	28.1%
Market Segment Drivers	The prevalence of infectious diseases has been increasing, which surges the demand for testing units to arrest pathogens. Epidemics create more demand for testing kits, another market driver. Rapid testing is required in the case of infectious disease, which requires an in-vitro diagnostics kit. Hence, it is another critical driver.

Category	End Use - Hospital Laboratories
Market Share in 2024	43.2%
Market Segment Drivers	The number of patients reaching hospital laboratories has increased as their physician prescribes them. Hence, this is a primary market segment driver. Hospital laboratories produce accurate test results with the help of in-vitro diagnostics test kits. Hence, this is a key segment driver.

Report Scope

Attributes	Details
Estimated Market Size in 2024	US$ 12.2 billion
Projected Market Valuation in 2034	US$ 18.8 billion
Value-based CAGR 2024 to 2034	4.40%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	Value in US$ billion
Key Regions Covered	North America Latin America Western Europe Eastern Europe South Asia and Pacific East Asia The Middle East and Africa
Key Market Segments Covered	Kits Format Application End Use Region
Key Countries Profiled	The United States Canada Brazil Mexico Germany The United Kingdom France Spain Italy Poland Russia Czech Republic Romania India Bangladesh Australia New Zealand China Japan South Korea GCC Countries South Africa Israel
Key Companies Profiled	Bio-Rad Laboratories Inc. Corning Incorporated DWK Life Sciences. Greiner Bio-One International GmbH Narang Medical Limited Thermo Fisher Scientific Inc. Sarstedt AG & Co. KG Aptar Group Incorporated West Pharmaceutical Services Cardinal Health Atlas Medical CareDx Inc. Altona Diagnostics GmbH Mylab Discovery Solutions Pvt. Ltd. Becton, Dickinson and Company Amcor Limited GBF Inc. Co-Diagnostics Inc. Epitope Diagnostics Inc. Integrated DNA Technologies Inc. AusDiagnostics

The market was valued at USD 90,400 million in 2025 and is anticipated to reach USD 146,500 million by 2035, expanding at a compound annual growth rate (CAGR) of 4.8% over the forecast period.

Metric	Value
Market Size (2025E)	USD 90,400 million
Market Value (2035F)	USD 146,500 million
CAGR (2025 to 2035)	4.8%

Country-wise Outlook

Country	CAGR (2025 to 2035)
United States	4.5%

Country	CAGR (2025 to 2035)
United Kingdom	4.2%

Region	CAGR (2025 to 2035)
European Union	4.3%

Country	CAGR (2025 to 2035)
Japan	4.4%

Country	CAGR (2025 to 2035)
South Korea	4.6%

Competitive Outlook

Company Name	Estimated Market Share (%)
Roche Diagnostics	20-24%
Abbott Laboratories	15-19%
Siemens Healthineers	12-16%
Danaher Corporation	10-14%
Other Companies (Combined)	30-40%